Compare GSK plc (GSK) vs NetFlix Inc (NFLX) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Netflix (NFLX) trades at $73.53, down 0.41% on the day and approaching its 52-week low. The technical picture remains bearish with strong selling pressure, while fundamentals show robust revenue growth to $45.18B in 2025 and net income of $10.98B. Recent earnings beat expectations with Q1 2026 EPS of $1.23 versus $0.76 expected, though the stock faces negative momentum amid concerns about growth sustainability.

Despite current bearish technicals, Netflix maintains strong fundamentals with 65% analyst buy ratings and a $103.64 consensus price target suggesting 41% upside. Key opportunities include advertising revenue scaling toward $3B by 2026 and expanding global market share. Risks include intense streaming competition and execution challenges in new business verticals like live sports and gaming.